Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21709368 | 0.89 | NUDT1 (0.42) | NUDT1MEN1GAAMAPTKMT2A | |
| SCHEMBL21709418 | 0.88 | NUDT1 (0.40) | NUDT1MEN1KMT2ASCN9AADORA2A | |
| SCHEMBL21709417 | 0.87 | NUDT1 (0.47) | NUDT1MEN1GAAMAPTKMT2A | |
| SCHEMBL21709222 | 0.87 | NUDT1 (0.44) | NUDT1MEN1GAAMAPTKMT2A | |
| SCHEMBL21709283 | 0.87 | NUDT1 (0.44) | NUDT1MEN1GAAMAPTKMT2A | |
| SCHEMBL21709299 | 0.85 | NUDT1 (0.38) | NUDT1 | |
| SCHEMBL23605512 | 0.85 | NUDT1 (0.41) | NUDT1MEN1KMT2ASCN9AADORA2A | |
| SCHEMBL21709372 | 0.84 | NUDT1 (0.43) | NUDT1MEN1GAAMAPTKMT2A | |
| SCHEMBL21709220 | 0.82 | NUDT1 (0.46) | NUDT1MEN1GAAMAPTKMT2A | |
| SCHEMBL25797038 | 0.82 | NUDT1 (0.33) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | DDT, NAT1, INMT | NUDT1 15/4885MEN1 2014/4885GAA 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.